🔎 Trials Near Me

Home › Esophageal Adenocarcinoma › Pennsylvania › Pittsburgh

Esophageal Adenocarcinoma clinical trials in Pittsburgh, PA

8 studies for Esophageal Adenocarcinoma are looking for participants at sites in and around Pittsburgh (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

RecruitingPhase 2/3
  • UPMC-Saint Margaret, Pittsburgh
  • UPMC Hillman Cancer Center, Pittsburgh
  • UPMC-Passavant Hospital, Pittsburgh
  • and 4 more
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT06203600

Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia

Recruiting
  • University of Pittsburgh Medical Center, Pittsburgh
Ages 18 to 89 · All sexes · Updated Sep 11, 2026 · NCT05753748

A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors

RecruitingPhase 1
  • University of Pittsburg Medical Center _UPMC Hillman Cancer Center, Pittsburgh
Ages 18 and older · All sexes · Updated Jul 15, 2026 · NCT06657144

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

RecruitingPhase 2
  • UPMC Hillman Cancer Center, Pittsburgh
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT04114136

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

RecruitingPhase 2
  • UPMC Hillman Cancer Center, Pittsburgh
Ages 18 and older · All sexes · Updated Apr 16, 2026 · NCT07223424

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

RecruitingPhase 1/2
  • UPMC Hillman Cancer Center, Pittsburgh
Ages 18 and older · All sexes · Updated Jan 21, 2026 · NCT03539822

Esophageal Adenocarcinoma trials in other cities

Other studies in Pittsburgh

From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.